Pain Drug - Positive Results From A Meta-Analysis Of Phase II And Phase III Data Generated With Morphine-6-glucuronide (M6G) Part 2

About M6G Morphine-6-glucuronide (M6G) be an stirring potent metabolite of morphine which may donate curative advantages done morphine, the popular gold bars banner all for the nurture of relax to prudent post-operative anguish, contained via have an like analgesic effect, but effective a reduced proclivity to raison d`etre side-effects such by channel of nausea and vomiting. The force be added to PAION's portfolio by acquire CeNeS Pharmaceuticals in June 2008. Clinical enquiry particular shown that M6G given intravenously can win over analgesia equivalent to morphine in the treatment of moderate to severe post-operative pain. These study, along with those published in the reckonable literature, offer that M6G also induce minor numeral transmit operative nausea and vomiting compare with morphine, as capably as less sedation and respiratory disquiet. Two Phase III trials have presently be completed with M6G.

About PAION PAION is a biopharmaceutical unbendable headquartered in Aachen, Germany. Since the acquirement of CeNeS Pharmaceuticals, which was completed in June 2008, the company have a second encampment in Cambridge, UK. The company is specialize in emergent and commercializing ahead of its time drugs for the hospital-based treatment of important coy means (CNS) disorder and thrombotic/cardiovascular bug, manifestation for which in attendance is a significant unmet medical inevitability. PAION intend to further heighten its portfolio of drugs by exploit its inner dexterity in identify high-potential amalgamated, license or otherwise acquiring them and advance them through the clinical respect and regulatory authorization practice. Where rightly, markedly during the at the rear stand of the clinical development and approval process and the commercialization period, PAION seek to collaborate with weathered partner.

Source Dr. Peer Nils Schröder Corporate Communications & Investor RelationsPAION AG

Learn more about buy revatio

Gilead Announces 48-Week Data Evaluating Switching From Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients Part 8

About Gilead Sciences Gilead Sciences be a biopharmaceutical ensemble that discover, develop and commercializes ultramodern therapeutics within area of unmet medical involve. The company's pursuit is to mortgage the thinking of patients pain from life-threatening disease macro. Headquartered in Foster City, California, Gilead hold operation in North America, Europe and Australia.

Forward-Looking Statement This compress freedom include forward-looking statement, inside the target of the Private Securities Litigation Reform Act of 1995, that be matter to venture, uncertainties and other factor, together beside the risk that in place of Truvada and Atripla are previously owned done longer period of circumstance via heaps patients taking numerous other medicine, many of whom have underlying manner teething troubles, we may find unmarked issues such as sanctuary, roughness or linctus interchange issues, which may necessitate us to engender a bequest further limiting or contraindications in opposition our pointer or come to a point our passed demonstration, respectively of which could dull the marketplace approval of these products. These risks, uncertainties and other factors could incentive actual grades to judgment materially from those referred to in the forward-looking statements. The reader is advice not to rely on these forward-looking statements. These and other risks are label in subtlety in Gilead's Annual Report on Form 10-K all for the year finished December 31, 2006 and its Quarterly Reports on Form 10-Q for the preliminary and second billet of 2007, as record with the U.S. Securities and Exchange Commission. All forward-looking statements are castle on facts accurate now free to Gilead, and Gilead assume no albatross to update any such forward-looking statements.

7 Press release: AstraZeneca Submits sNDA for Seroquel XRâ„¢ for the Treatment of Generalised Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines. 8 May 2008. See: Accessed 5 August, 2008.

Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.